CA3129835A1 - Crispr/cas fusion proteins and systems - Google Patents

Crispr/cas fusion proteins and systems Download PDF

Info

Publication number
CA3129835A1
CA3129835A1 CA3129835A CA3129835A CA3129835A1 CA 3129835 A1 CA3129835 A1 CA 3129835A1 CA 3129835 A CA3129835 A CA 3129835A CA 3129835 A CA3129835 A CA 3129835A CA 3129835 A1 CA3129835 A1 CA 3129835A1
Authority
CA
Canada
Prior art keywords
cell
protein
sequence
fusion protein
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3129835A
Other languages
English (en)
French (fr)
Inventor
Fuqiang Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Aldrich Co LLC
Original Assignee
Sigma Aldrich Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Aldrich Co LLC filed Critical Sigma Aldrich Co LLC
Publication of CA3129835A1 publication Critical patent/CA3129835A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/60Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
CA3129835A 2019-02-15 2020-02-13 Crispr/cas fusion proteins and systems Pending CA3129835A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806708P 2019-02-15 2019-02-15
US62/806,708 2019-02-15
PCT/US2020/018145 WO2020168102A1 (en) 2019-02-15 2020-02-13 Crispr/cas fusion proteins and systems

Publications (1)

Publication Number Publication Date
CA3129835A1 true CA3129835A1 (en) 2020-08-20

Family

ID=70166116

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3129835A Pending CA3129835A1 (en) 2019-02-15 2020-02-13 Crispr/cas fusion proteins and systems

Country Status (11)

Country Link
US (3) US10947517B2 (enExample)
EP (1) EP3924475A1 (enExample)
JP (2) JP2022520104A (enExample)
KR (1) KR20210139271A (enExample)
CN (1) CN113728099A (enExample)
AU (2) AU2020221274B2 (enExample)
BR (1) BR112021016019A2 (enExample)
CA (1) CA3129835A1 (enExample)
IL (1) IL285300A (enExample)
SG (1) SG11202108812SA (enExample)
WO (1) WO2020168102A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
EP3924475A1 (en) 2019-02-15 2021-12-22 Sigma-Aldrich Co. LLC Crispr/cas fusion proteins and systems
AU2022343268A1 (en) * 2021-09-08 2024-03-28 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
CN116063546A (zh) * 2021-10-29 2023-05-05 深圳先进技术研究院 一种基于共振能量转移的全遗传编码nad+蛋白探针及其制备方法和应用
US20230265405A1 (en) * 2022-02-22 2023-08-24 Massachusetts Institute Of Technology Engineered nucleases and methods of use thereof
WO2025221793A1 (en) * 2024-04-16 2025-10-23 Monsanto Technology Llc Modified cas proteins for nuclear localization and editing activity in plants

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002360424A1 (en) 2001-11-26 2003-06-10 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
MY189533A (en) 2012-05-25 2022-02-16 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
AU2013355214B2 (en) * 2012-12-06 2017-06-15 Sigma-Aldrich Co. Llc Crispr-based genome modification and regulation
WO2014186686A2 (en) * 2013-05-17 2014-11-20 Two Blades Foundation Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases
CN105555317A (zh) * 2013-06-11 2016-05-04 药物运输有限公司 与特异性生物活性货物肽偶联的源自人类的细胞渗透肽的结构、制造和用途
WO2015089486A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
JP6605482B2 (ja) * 2014-02-19 2019-11-13 バイオアシス テクノロジーズ インコーポレイテッド P97−ids融合タンパク質
US11242525B2 (en) 2014-03-26 2022-02-08 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating sickle cell disease
KR102630014B1 (ko) 2014-10-01 2024-01-25 더 제너럴 하스피탈 코포레이션 뉴클레아제-유도 상동성-지정 복구의 효율 증가 방법
US20160376610A1 (en) * 2015-06-24 2016-12-29 Sigma-Aldrich Co. Llc Cell cycle dependent genome regulation and modification
JP6867689B2 (ja) * 2016-01-29 2021-05-12 国立大学法人東京工業大学 Cas9−gRNA複合体の細胞核内への導入方法、及び細胞内における標的遺伝子の改変方法
WO2017173004A1 (en) * 2016-03-30 2017-10-05 Mikuni Takayasu A method for in vivo precise genome editing
US11236313B2 (en) 2016-04-13 2022-02-01 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
CN107579793A (zh) * 2016-07-04 2018-01-12 中兴通讯股份有限公司 一种通信网络设备间时间同步的优化方法、装置及设备
JP7231935B2 (ja) * 2016-08-03 2023-03-08 プレジデント アンド フェローズ オブ ハーバード カレッジ アデノシン核酸塩基編集因子およびそれらの使用
EP3497214B1 (en) 2016-08-09 2023-06-28 President and Fellows of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
EP3526320A1 (en) * 2016-10-14 2019-08-21 President and Fellows of Harvard College Aav delivery of nucleobase editors
AU2016432443B2 (en) 2016-12-14 2024-04-18 Stichting Voor De Technische Wetenschappen Thermostable Cas9 nucleases
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
KR20250096876A (ko) 2017-07-31 2025-06-27 리플렉션 바이오테크놀러지스 리미티드 안과 질환을 위한 세포 모델 및 치료요법
US11071791B2 (en) * 2018-01-26 2021-07-27 Wisconsin Alumni Research Foundation Vector for gene silencing and replacement and methods of use thereof
JP7109547B2 (ja) 2018-02-15 2022-07-29 シグマ-アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー 真核ゲノム修飾のための操作されたCas9システム
WO2019178427A1 (en) * 2018-03-14 2019-09-19 Arbor Biotechnologies, Inc. Novel crispr dna targeting enzymes and systems
EP3924475A1 (en) 2019-02-15 2021-12-22 Sigma-Aldrich Co. LLC Crispr/cas fusion proteins and systems

Also Published As

Publication number Publication date
US20210163910A1 (en) 2021-06-03
EP3924475A1 (en) 2021-12-22
BR112021016019A2 (pt) 2021-10-05
CN113728099A (zh) 2021-11-30
AU2020221274B2 (en) 2024-02-08
US11965184B2 (en) 2024-04-23
IL285300A (en) 2021-09-30
AU2024202275A1 (en) 2024-05-23
JP2023156365A (ja) 2023-10-24
KR20210139271A (ko) 2021-11-22
WO2020168102A1 (en) 2020-08-20
US10947517B2 (en) 2021-03-16
SG11202108812SA (en) 2021-09-29
AU2020221274A1 (en) 2021-08-26
US20230287377A1 (en) 2023-09-14
US20200263155A1 (en) 2020-08-20
JP2022520104A (ja) 2022-03-28

Similar Documents

Publication Publication Date Title
AU2021245148B2 (en) Using nucleosome interacting protein domains to enhance targeted genome modification
US12297449B2 (en) Engineered CAS9 systems for eukaryotic genome modification
KR102458395B1 (ko) 프로그램가능한 dna 결합 단백질을 사용한, 표적화된 게놈 변형의 개선
US11965184B2 (en) CRISPR/Cas fusion proteins and systems

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210810

EEER Examination request

Effective date: 20210810

EEER Examination request

Effective date: 20210810

EEER Examination request

Effective date: 20210810

EEER Examination request

Effective date: 20210810

EEER Examination request

Effective date: 20210810

EEER Examination request

Effective date: 20210810

EEER Examination request

Effective date: 20210810